

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



TYK Medicines, Inc
浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2410)

NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2025

NOTICE IS HEREBY GIVEN THAT the first extraordinary general meeting of 2025 (the “**EGM**”) of TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “**Company**”) will be held at 8th Floor, Building T2, China Eastern Binjiang Center, No. 277 Longlan Road, Xuhui District, Shanghai, the PRC at 1:00 p.m. on Friday, January 3, 2025 for the purpose of considering and, if though fit, passing the following resolutions. Unless otherwise defined, capitalized terms used in this notice shall have the same meanings as those defined in the circular of the Company dated December 19, 2024.

ORDINARY RESOLUTIONS

1. To consider and approve the proposed adjustment to remuneration of the executive Directors and the independent non-executive Directors:
 - (i) To consider and approve the proposed adjustment to remuneration of Dr. Wu Yusheng;
 - (ii) To consider and approve the proposed adjustment to remuneration of Dr. Jiang Mingyu;
 - (iii) To consider and approve the proposed adjustment to remuneration of Mr. Zhang Shenquan;
 - (iv) To consider and approve the proposed adjustment to remuneration of Dr. Leng Yuting;
 - (v) To consider and approve the proposed adjustment to remuneration of Dr. Xu Wenqing;

- (vi) To consider and approve the proposed adjustment to remuneration of Dr. Shen Xiuhua.
2. To consider and approve the proposed purchase of fixed assets.
 3. To consider and approve the proposed establishment of a wholly-owned subsidiary in Hong Kong.
 4. To consider and approve the proposed authorization to the board of directors in respect of external investment and acquisition and disposal of assets.
 5. To consider and approve the proposed establishment of a wholly-owned subsidiary for macromolecular drug R&D.

SPECIAL RESOLUTION

6. To consider and approve the proposed amendments to the Articles of Association.

By Order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)

Dr. Wu Yusheng
Chairman, Executive Director and Chief Executive Officer

Hong Kong
December 19, 2024

Notes:

1. All resolutions at the EGM will be taken by poll (except where the chairman decides to allow a resolution relating to a procedural or administrative matter to be voted on by a show of hands) pursuant to the Listing Rules. The results of the poll will be published on the websites of the Company at www.tykmedicines.com and the Stock Exchange at www.hkexnews.hk after the EGM.
2. Any shareholder entitled to attend and vote at the EGM convened by the above notice is entitled to appoint one or more proxies to attend and vote instead of him/her. A proxy need not be a shareholder of the Company.
3. In order to be valid, the instrument appointing a proxy together with the power of attorney or other authority, if any, under which it is signed, or a notarially certified copy of such power of attorney or authority, must be completed and returned to the H share registrar of the Company, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong (for holders of H shares), at least 24 hours before the EGM (i.e. before 1:00 p.m. on Thursday, January 2, 2025) or any adjourned meeting thereof. Completion and return of the form of proxy will not preclude a shareholder from attending and voting in person at the EGM or any adjourned meeting thereof should he/she so wish.
4. For the purpose of determining the list of holders of H shares who are entitled to attend the EGM, the H share register of members of the Company will be closed on Friday, January 3, 2025, on which day, no transfer of shares will be registered. In order to be eligible to attend and vote at the EGM, all transfer documents accompanied by the relevant share certificates must be lodged with the H share registrar of the Company, Computershare Hong Kong Investor Services Limited at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong no later than 4:30 p.m. on Thursday, January 2, 2025 for registration.
5. Where there are joint registered holders of any share, any one of such joint holders may vote, either in person or by proxy, in respect of such share as if he/she was solely entitled thereto, but if more than one of such joint holders are present at the EGM, whether in person or by proxy, the joint registered holder present whose name stands first on the register of members of the Company in respect of the shares shall alone be entitled to vote in respect thereof.
6. A shareholder or his/her/its proxy should produce proof of identity when attending the EGM.
7. The EGM is expected to last for no more than half a business day. Shareholders and proxies attending the meeting shall be responsible for their own travel and accommodation expenses.
8. Shareholders may contact the Company at mingyu.jiang@tykmedicines.com or jiayi.wu@tykmedicines.com for any enquiries in respect of the EGM.

As at the date of this notice, the board of directors of the Company comprises Dr. Wu Yusheng and Dr. Jiang Mingyu as executive directors, Dr. Li Jun, Dr. Gu Eric Hong, Dr. Meng Xiaoying, Mr. He Chao and Dr. Ding Zhao as non-executive directors, and Mr. Zhang Senquan, Dr. Leng Yuting, Dr. Xu Wenqing and Dr. Shen Xiuhua as independent non-executive directors.